<DOC>
	<DOC>NCT02900404</DOC>
	<brief_summary>This study shall determine whether XAPPORT - a mobile device app based on different guidelines, the summary of product characteristics of rivaroxaban, and clinical facts and practice - provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.</brief_summary>
	<brief_title>Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm</brief_title>
	<detailed_description>Study design: "retrospective/prospective" Observational study</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Female or male patient â‰¥18 years who provided signed and dated informed consent to the use of their medical data Patient was treated with rivaroxaban before and after surgery because of nonvalvular atrial fibrillation (NVAF) or venous thromboembolism/pulmonary embolism (VTE/PE) Elective surgery in a department of General Surgery or Orthopedics / Trauma Surgery was performed within the last 12 months before study start The patient has been discharged from hospital Patient's medical records are available for data entry Patient participated in an interventional drug study within 3 months prior to the surgery and discharge from hospital</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>